Core Viewpoint - Several financial institutions have initiated coverage on various companies with positive ratings, indicating strong potential for growth and investment opportunities in their respective markets [1] Group 1: Company Initiations - UBS initiated coverage of Carvana (CVNA) with a Buy rating and a price target of $450, highlighting its "differentiated, best-in-class" online platform and customer experience, which positions it well in the large used vehicle market [1] - Benchmark initiated coverage of Cal-Maine Foods (CALM) with a Buy rating and a price target of $100, suggesting that the company's valuation is undervalued due to its legacy as a commodity producer, despite significant changes in the egg category and a shift towards more valuable specialty production [1] - Goldman Sachs initiated coverage of Beta Technologies (BETA) with a Buy rating and a price target of $47, viewing it as the best positioned among electric vertical take-off and landing companies, with multiple other firms also starting coverage with Buy-equivalent ratings [1] - JPMorgan initiated coverage of BillionToOne (BLLN) with an Overweight rating and a price target of $150, noting the company's potential to build its commercial infrastructure to meet growing demand in prenatal and oncology sectors, with several other firms also starting coverage with Buy-equivalent ratings [1] - Morgan Stanley initiated coverage of Evommune (EVMN) with an Overweight rating and a price target of $36, seeing favorable risk/reward for the shares despite early-stage data for its products, with other firms also starting coverage with Buy-equivalent ratings [1]